Tesaro

AstraZeneca takes PARP battle to court, seeking a larger claim to GSK's key cancer med Zejula: report
Fierce Pharma
Mon, 06/7/21 - 08:45 pm
GSK
Tesaro
AstraZeneca
legal
Zejula
Lynparza
With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy
Endpoints
Mon, 10/26/20 - 11:15 am
AnaptysBio
GSK
Tesaro
Zejula
GSK posts middling data from PD-1 Tesaro buyout drug
Fierce Biotech
Fri, 04/24/20 - 11:00 am
GSK
Tesaro
dostarlimab
clinical trials
endometrial cancer
GSK wins speedy FDA Zejula review in ovarian cancer niche
Fierce Pharma
Mon, 06/24/19 - 07:13 pm
GSK
FDA
Zejula
ovarian cancer
late-stage ovarian cancer
Tesaro
Will GSK/Tesaro’s Checkpoint Inhibitor Be Able to Compete With Merck’s Keytruda?
BioSpace
Wed, 03/20/19 - 12:27 pm
GSK
Tesaro
Merck
Keytruda
endometrial cancer
dostarlimab
After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck
Endpoints
Tue, 02/5/19 - 09:52 am
GSK
Merck KGaA
Tesaro
immunotherapy
GSK closes acquisition of Tesaro for $5.1bn
Pharmaceutical Business Review
Wed, 01/23/19 - 10:39 am
GSK
Tesaro
M&A
oncology
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
Biopharma Dive
Thu, 01/10/19 - 12:31 pm
Editas
CRISPR
GSK
Tesaro
Clovis Oncology
M&A
AbbVie
JPMHC 2019
Class Action Lawsuit Aims to Halt GSK Acquisition of Tesaro
BioSpace
Tue, 01/8/19 - 07:10 pm
GSK
M&A
Tesaro
shareholders
Clovis dips as Tesaro reveals more details of its acquisition
Biopharma Dive
Wed, 12/19/18 - 12:33 am
Clovis Oncology
Tesaro
M&A
Tesaro execs split $304M windfall from $5.1B GlaxoSmithKline buyout
Endpoints
Mon, 12/17/18 - 09:14 am
Tesaro
executive pay
M&A
GSK
Anatomy of a long-delayed biotech buyout: With its stock price beaten down, abandoned by potential bidders, Tesaro wound up in GSK’s eager arms
Endpoints
Sat, 12/15/18 - 11:44 pm
M&A
Tesaro
Zejula
GSK
Should You Be Worried About the Return of Big Pharma Deals?
Motley Fool
Tue, 12/4/18 - 11:27 am
GSK
Tesaro
M&A
Big Pharma
JNJ
Argenx
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
Xconomy
Mon, 12/3/18 - 10:11 am
GSK
M&A
Tesaro
PARP inhibitors
Zejula
AstraZeneca
Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to be on the Market
BioSpace
Mon, 11/19/18 - 11:25 am
Tesaro
Roche
Gilead Sciences
M&A
Tesaro stock rebounds on takeout report
BioCentury
Sat, 11/17/18 - 12:53 pm
Tesaro
M&A
Investors ding Tesaro despite responses for combo in NSCLC
BioCentury
Sat, 11/10/18 - 12:44 pm
Tesaro
non-small cell lung cancer
clinical trials
TSR-042
PARP makers search for a way to break through
Biopharma Dive
Fri, 11/9/18 - 12:08 am
AstraZeneca
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
Wed, 10/24/18 - 12:38 pm
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
How Tesaro Hopes to Tackle Lung Cancer
Motley Fool
Fri, 09/7/18 - 11:07 am
Tesaro
TSR-042
non-small cell lung cancer

Pages